Pedro M Machado1, Mazen M Dimachkie, Richard J Barohn. 1. aMRC Centre for Neuromuscular Diseases, University College London, London, UK bDepartment of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA.
Abstract
PURPOSE OF THE REVIEW: To describe new insights and developments in the pathogenesis, diagnosis and treatment of sporadic inclusion body myositis (IBM). RECENT FINDINGS: Various hypothesis about the pathogenesis of IBM continue to be investigated, including autoimmune factors, mitochondrial dysfunction, protein dyshomeostasis, altered nucleic acid metabolism, myonuclear degeneration and the role of the myostatin pathway. Serum autoantibodies against cytosolic 5'-nucleotidase 1A have been identified in IBM showing moderate diagnostic performance. The differential diagnostic value of histopathological features, including different protein aggregates, continues to be evaluated. MRI may also be of monitoring value in IBM. New therapeutic strategies are being tested in IBM patients, namely the upregulation of the heat shock response and the antagonism of myostatin. SUMMARY: Recent important advances have occurred in IBM. These advances, including recent and ongoing clinical trials, may lead to earlier diagnosis and improved understanding and treatment of the disease. Despite improved knowledge, IBM continues to be a puzzling disease and the pathogenesis remains to be clarified. An interdisciplinary, bench to bedside translational research approach is crucial for the successful identification of novel treatments for this debilitating, currently untreatable disorder.
PURPOSE OF THE REVIEW: To describe new insights and developments in the pathogenesis, diagnosis and treatment of sporadic inclusion body myositis (IBM). RECENT FINDINGS: Various hypothesis about the pathogenesis of IBM continue to be investigated, including autoimmune factors, mitochondrial dysfunction, protein dyshomeostasis, altered nucleic acid metabolism, myonuclear degeneration and the role of the myostatin pathway. Serum autoantibodies against cytosolic 5'-nucleotidase 1A have been identified in IBM showing moderate diagnostic performance. The differential diagnostic value of histopathological features, including different protein aggregates, continues to be evaluated. MRI may also be of monitoring value in IBM. New therapeutic strategies are being tested in IBM patients, namely the upregulation of the heat shock response and the antagonism of myostatin. SUMMARY: Recent important advances have occurred in IBM. These advances, including recent and ongoing clinical trials, may lead to earlier diagnosis and improved understanding and treatment of the disease. Despite improved knowledge, IBM continues to be a puzzling disease and the pathogenesis remains to be clarified. An interdisciplinary, bench to bedside translational research approach is crucial for the successful identification of novel treatments for this debilitating, currently untreatable disorder.
Authors: C Cantwell; M Ryan; M O'Connell; P Cunningham; D Brennan; D Costigan; T Lynch; S Eustace Journal: Clin Radiol Date: 2005-02 Impact factor: 2.350
Authors: Karolina A Rygiel; James Miller; John P Grady; Mariana C Rocha; Robert W Taylor; Doug M Turnbull Journal: Neuropathol Appl Neurobiol Date: 2015-04 Impact factor: 8.090
Authors: Anne-Katrin Güttsches; Stefen Brady; Kathryn Krause; Alexandra Maerkens; Julian Uszkoreit; Martin Eisenacher; Anja Schreiner; Sara Galozzi; Janine Mertens-Rill; Martin Tegenthoff; Janice L Holton; Matthew B Harms; Thomas E Lloyd; Matthias Vorgerd; Conrad C Weihl; Katrin Marcus; Rudolf A Kley Journal: Ann Neurol Date: 2017-01-27 Impact factor: 10.422
Authors: Qiang Gang; Conceicao Bettencourt; Pedro M Machado; Zoe Fox; Stefen Brady; Estelle Healy; Matt Parton; Janice L Holton; David Hilton-Jones; Perry B Shieh; Edmar Zanoteli; Boel De Paepe; Jan De Bleecker; Aziz Shaibani; Michela Ripolone; Raffaella Violano; Maurizio Moggio; Richard J Barohn; Mazen M Dimachkie; Marina Mora; Renato Mantegazza; Simona Zanotti; Michael G Hanna; Henry Houlden Journal: Neurobiol Aging Date: 2015-01-14 Impact factor: 4.673
Authors: Qiang Gang; Conceição Bettencourt; Pedro M Machado; Stefen Brady; Janice L Holton; Alan M Pittman; Deborah Hughes; Estelle Healy; Matthew Parton; David Hilton-Jones; Perry B Shieh; Merrilee Needham; Christina Liang; Edmar Zanoteli; Leonardo Valente de Camargo; Boel De Paepe; Jan De Bleecker; Aziz Shaibani; Michela Ripolone; Raffaella Violano; Maurizio Moggio; Richard J Barohn; Mazen M Dimachkie; Marina Mora; Renato Mantegazza; Simona Zanotti; Andrew B Singleton; Michael G Hanna; Henry Houlden Journal: Neurobiol Aging Date: 2016-08-08 Impact factor: 4.673